Bob Gower Biography and Net Worth

Director of Ensysce Biosciences

Dr. Gower was Chief Executive Officer of Lyondell Petrochemical from 1985 through his retirement at the end of 1996. Together with Dr. Richard Smalley, Dr. Gower founded Carbon Nanotechnologies, Inc. (“CNI”) in 2000 developing fullerene carbon nanotubes for multiple applications. CNI was acquired by Unidym in 2007. Dr. Gower founded Specified Fuels and Chemicals and in early 2008, founded Ensysce for the specific focus of using carbon nanotubes in therapeutic areas. He served on the board of directors of numerous companies, including Kirby Corporation and OmNova. In addition, Dr. Gower received his Ph.D. from the University of Minnesota.

What is Bob G. Gower's net worth?: The estimated net worth of Bob G. Gower is at least $222.09 thousand as of April 23rd, 2026. Dr. Gower owns 516,740 shares of Ensysce Biosciences stock worth more than $222,095 as of October 7th. This net worth evaluation does not reflect any other investments that Dr. Gower may own. Learn More about Bob G. Gower's net worth.
How do I contact Bob G. Gower?: The corporate mailing address for Dr. Gower and other Ensysce Biosciences executives is 7946 Ivanhoe Avenue, Suite 201, LA Jolla, CA, 92037. Ensysce Biosciences can also be reached via phone at 858-263-4196 and via email at [email protected]. Learn More on Bob G. Gower's contact information.
Has Bob G. Gower been buying or selling shares of Ensysce Biosciences?: Bob G. Gower has not been actively trading shares of Ensysce Biosciences during the past quarter. Most recently, on Friday, August 7th, Bob G. Gower bought 400,000 shares of Ensysce Biosciences stock. The stock was acquired at an average cost of $0.49 per share, with a total value of $196,000.00. Following the completion of the transaction, the director now directly owns 916,740 shares of the company's stock, valued at $449,202.60. Learn More on Bob G. Gower's trading history.
Are insiders buying or selling shares of Ensysce Biosciences?: In the last twelve months, Ensysce Biosciences insiders bought shares 2 times. They purchased a total of 908,614 shares worth more than $440,134.72. The most recent insider tranaction occured on August, 7th when Director Bob G. Gower bought 400,000 shares worth more than $196,000.00. Insiders at Ensysce Biosciences own 2.8% of the company. Learn More about insider trades at Ensysce Biosciences.
Information on this page was last updated on 8/7/2026.

Bob G. Gower Insider Trading History at Ensysce Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/7/2026	Buy	400,000	$0.49	$196,000.00	916,740
4/23/2026	Buy	508,614	$0.48	$244,134.72	516,740
3/2/2023	Buy	501	$88.20	$44,188.20	6,792

Bob G. Gower Buying and Selling Activity at Ensysce Biosciences

Ensysce Biosciences Company Overview

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Today's Range

Now: $0.43

$0.42

$0.44

50 Day Range

MA: $0.41

$0.25

$0.52

2 Week Range

Now: $0.43

$0.23

$2.75

Volume

43,508 shs

Average Volume

7,402,800 shs

Market Capitalization

$8.31 million

P/E Ratio

N/A

Dividend Yield